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ABSTRACT
Inborn errors of metabolism are a heterogeneous class of multisystemic diseases which, although individually rare, are collectively quite 
common. Central nervous system is usually affected.
The authors report the case of a five-month-old girl, daughter of non-consanguineous parents, born after an unremarkable full-term 
pregnancy and delivery. Hypotonia and neurodevelopmental regression were noted from the age of five months, along with progressive onset 
of facial dysmorphism, hepatomegaly, seizures, and dilated cardiomyopathy. Gangliosidosis type 1 diagnosis was confirmed by biochemical, 
enzymatic, and genetic findings.
This report enhances the relevance of multidisciplinary approach and follow-up.
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RESUMO
Os erros hereditários do metabolismo são um grupo de doenças heterogéneas e multissistémicas. Apesar de cada doença individualmente 
ser rara, no seu conjunto são relativamente comuns. O sistema nervoso central é habitualmente afetado.  
Os autores apresentam o caso de uma lactente de cinco meses de idade, filha de pais não consanguíneos, nascida de uma gravidez de termo 
e parto sem intercorrências. Aos cinco meses, iniciou um quadro de hipotonia e regressão do desenvolvimento, apresentando ao longo do 
tempo dismorfismo facial, hepatomegália, convulsões e cardiomiopatia dilatada. O diagnóstico de Gangliosidose tipo 1 foi confirmado por 
achados bioquímicos, enzimáticos e genéticos. 
Este caso clínico reforça a relevância de uma abordagem e seguimento multidisciplinares.
Palavras-chave: Doença lissosomal de sobrecarga; face grosseira; Gangliosidose; hipotonia; regressão do desenvolvimento
NASCER E CRESCER
BIRTH AND GROWTH MEDICAL JOURNAL
year 2020, vol XXIX, n.º 2
118
INTRODUCTION
Inborn errors of metabolism (IEMs) are a wide and heterogeneous 
group of diseases resulting from the absence or deficiency of an 
enzyme or its cofactor, leading to either accumulation or deficiency 
of specific metabolites. Each hereditary metabolic disease is a rare 
entity, but collectively they represent a frequent clinical finding. 
IEMs can affect any organ or system. Neurological are among the 
most common findings, namely developmental delay or regression, 
epilepsy, or abnormal muscular tone. Dysmorphic features can also 
occur in some diseases in this group and may be present from birth 
or develop throughout life.1
Lysosomal storage disorders (LSD) are one group of IEMs in which 
the enzymatic defect leads to accumulation of undegraded insoluble 
metabolites within lysosomes. Gangliosidosis type 1 (GM1) is a severe 
LSD with important central nervous system (CNS) involvement.1
CASE REPORT
The authors report the case of a Caucasian girl referred at the age 
of five months to the General Pediatric consultation due to recurrent 
wheezing. 
The girl was the second child of healthy non-consanguineous 
parents. Her ten-year-old brother was healthy. No family history of 
genetic, neurological, or metabolic diseases and no previous sibling 
or fetal deaths were acknowledged.
Pregnancy was uneventful, with normal prenatal ultrasounds. The 
girl was born at 37 gestational weeks and six days by spontaneous 
vaginal delivery, with growth restriction:  she weighed 2410 g 
(3−10th percentile for gestational age and sex - Fenton growth 
chart2), was 45 cm height (3−10th percentile for gestational age and 
sex - Fenton growth chart), and had 32.5 cm of head circumference 
(10−50th percentile for gestational age and sex - Fenton growth 
chart).2 No complications were reported during delivery or perinatal 
period. Neonatal hearing screening with acoustic otoemissions 
revealed bilateral absence of evoked otoacoustic emission response, 
suggesting congenital hearing loss. Evoked audition potentials 
were inconclusive, but the exam could not be repeated. Congenital 
heart disease screening (with pulse oximetry) was normal, as well 
as neonatal metabolic screening. The patient had two previous 
admissions due to respiratory infection, at 3 and 4.5 months, with 
recurrent wheezing as sequelae. After discharge, she received inhaled 
fluticasone and was referred to the General Pediatric consultation.  
Physical examination at five months showed non-suspicious facial 
features. Cardiopulmonary auscultation and abdominal evaluation 
were normal, with no cardiac murmur or organomegaly. Neurological 
exam revealed predominantly bilateral fisted hand with forearm in 
a flexed and supine position. The patient held the head in seated 
position, maintained eye contact, and smiled. The remaining physical 
observation was normal.
At the age of six months, a significant neurodevelopmental 
regression was noted, with severe hypotonia and poor cephalic 
control. Hepatomegaly was also noted, but no facial abnormalities.
Ongoing follow-up revealed progressive facial feature change 
(Figure 1). Mild frontal bossing, thick eyebrows, depressed nasal 
bridge, and long philtrum were evidenced, as well as macroglossia, 
gingival hypertrophy, thickened skin, hirsutism, dorsal kyphosis, 
flexion hand contractures, and prominent abdomen with progressive 
hepatomegaly. At nine months, the girl was diagnosed with dilated 
cardiomyopathy (end-diastolic diameter of the left ventricle: 46 mm 
– Z-score 16) with left ventricular systolic function at the lower limit 
of normal (shortening fraction 28%) and moderate-to-severe mitral 
regurgitation due to anterior leaflet prolapse and annulus dilatation. 
At 11 months, she had her first seizure with generalized tonic-clonic 
movements.
Although neuromuscular and skeletal symptoms progressed, the 
patient started physiotherapy at the age of six months. Weight and 
height evolved on the 15th percentile and head circumference on 
the 15-50th percentile for age and sex, according to WHO Growth 
Charts.3
Figure 1 - Phenotypic feature evolution
Developmental regression preceded dysmorphic findings, leading 
to an extensive study. Magnetic resonance imaging, performed at 6.5 
months, showed narrowed corpus callosum thickness, slight normal 
myelinisation delay of cortical-spinal tract, and normal ventricle, 
brain, and cerebellum dimension. Ophthalmological examination 
revealed divergent strabismus with normal fundoscopy. Spine x-ray 
revealed severe scoliosis with anterior angle in dorsal and lumbar 
spine transition (Figure 2). Electroencephalography (at 11 months) 
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DISCUSSION/CONCLUSION
GM1 is an autosomal recessive LSD caused by β-galactosidase 
enzyme deficiency.4,5 It is a rare disease with an estimated incidence 
of 1 in 100,000-200,000 live births.4
GM1 can be classified into three types based on clinical phenotype, 
with disease severity inversely correlated with residual activity of the 
mutant enzyme.4 Type 1 or infantile form is the most severe form of 
disease, with onset between birth and six months, rapidly progressive 
course, and death by the age of 1–2 years.4 Classical symptoms are 
present in almost every patient by the time of diagnosis: coarse 
facial features (87%), cherry-red macula (59%), hepatosplenomegaly 
(85%), and skeletal dysostosis (82%). Cardiomyopathy is present in 
one third of GM1 cases and CNS involvement in all cases.4
β-galactosidase enzyme is encoded by GLB1 gene (E.C.3.2.1.23; 
MIM 230500), mapping on the 3p21.33 chromosome with 16 exons.6 
More than 130 genetic alterations have been reported in GLB1 gene 
to date. According to the literature, many patients are compound 
heterozygous, as in the present case, which confirms the extensive 
molecular heterogeneity of β-galactosidase gene and the difficulty in 
correlating genotype with phenotype.6,7 
Enzymatic deficiency leads to a massive storage of GM1 
ganglioside and related glycoconjugates (oligosaccharidosis and 
mucopolysaccharidosis) in different tissues, namely CNS, with 
progressive tissue destruction characteristic of GM1.4,8 Extraneuronal 
clinical involvement is related to oligo and mucopolysaccharide 
accumulation. Some authors suggest that phenotypic variability 
is explained by different substrate binding sites, protein folding-
relevant sites, or enzyme subdomains, required for catabolism 
of different substrates. Consequently, β-galactosidade mutations 
produce phenotypes with different degrees of neuronal dysfunction 
and extraneuronal signs and symptoms.4,8
GLB1 gene also encodes for elastin binding protein (EBP), located 
in the endosomal compartment. Its depletion in arterial smooth 
muscle, fibroblasts, and chondroblasts interferes with elastic fibre 
assembly, probably leading to skeletal and cardiac deformations.9,10 
Santamaria et al. reported that all cardiac disease patients had 
two GLB1 mutations affecting both lysosomal enzyme and EBP, 
suggesting that cardiac involvement is caused by an homozygous EBP 
alteration.6 However, findings from this study argue against this, as 
the patient only had one EBP-affecting mutation (c.1581G>A). Some 
authors argue that elastogenesis can also be disrupted by pericellular 
accumulation of galactosugar-bearing-moieties, such as chondroitin 
sulphate or dermatan sulphate, which bind to EBP and induce both 
its shedding from cell surface and premature tropoelastin release 
far from microfibrillar acceptors.10 This second mechanism acts as a 
secondary EBP defect and could help understand cardiac disease in 
the present patient.
There is no curative GM1 treatment at present, but therapeutic 
options are being investigated.
Until curative treatment emerges, all children and their families 
should be referred to palliative care for end-of-life support and 
quality of life improvement.4
In conclusion, GM1 is a rare disease with multisystemic involvement. 
Early diagnosis is challenging due to clinical heterogeneity, sign and 
symptom similarity with other IEMs, and their progressive onset 
over time. Awareness of multisystemic and progressive involvement 
showed diffuse lentification, with no seizure focus. 
Initial metabolic evaluation including ammonia, free amino acid and 
organic acid chromatographic analysis, redox state, and very long-
chain fatty acids was normal.
Lysosomal enzymatic activity measured in dried blood spots 
was low for α-L-iduronidase (0.08 nmol/h/spot; NR 0.10-0.9) and 
β-galactosidase (0.05 nmol/h/spot; NR 1.50-7.00) activity. The 
remaining enzymatic activity tests (iduronate-2-sulfatase, N-acetil-
α-D-glucosaminidase, galactosamine-6-sulfatase, arylsulfatase B, 
and β-glucuronidase) were all normal. Low β-galactosidase activity 
suggested Gangliosidosis type 1 (GM1) or Morquio disease type 
B.4 Glycosaminoglycans measured in urine were increased (104 
mg/mmol creatinine; normal range 4−31) and monodimensional 
electrophoresis revealed chondroitin-6-sulphate accumulation. 
Absence of increased keratane sulphate urinary excretion, along with 
clinical storage in neural tissues indicated GM1 as the most likely 
diagnosis.
Definite GM1 diagnosis was established following identification of 
a compound heterozygous mutation (c.588-591insT and c.1581G>A) 
on GLB1 gene at the age of 11 months.4 The girl’s parents were 
heterozygous for one of the mutations.
The girl was hospitalized several times due to pulmonary infections. 
She presented generalized hypotonia, lethargy, occasional seizures 
(partially controlled with levetiracetam and phenytoin) and profound 
mental retardation. Feeding skills persisted until she was 16 months 
old. After receiving palliative support, the girl died at the age of 18 
months. The family currently benefits from psychological support. 
Figure 2 - Spine radiograph at ten months old
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may be key to reach an early diagnosis and offer a complete and 
multidisciplinary therapeutic approach, together with genetic 
counselling including prenatal diagnostic options for the family. 
CONSENT
Informed consent for case, image, and laboratory study publication 
was previously obtained from the patient’s parents. Parents 
authorized case publication without feature hiding.
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